KEYNOTE-204
In KEYNOTE-204, PD-1 blockade beat the CD30 ADC head to head in relapsed Hodgkin lymphoma.
PFS 13.2 vs 8.3 months (HR 0.65); approved October 2020 for relapse after ≥1 line in adults and ≥2 lines in children.
Setting
Relapsed/refractory classical Hodgkin lymphoma: pembrolizumab vs brentuximab vedotin
Phase
Phase 3
Sponsor
Merck
Registry
Headline result
PFS 13.2 vs 8.3 months, HR 0.65.
Reported
2020
Enrolled
304
In plain words
What these results mean for people, not percentages
Progression-free survival (median)primarysurrogate endpoint
- Median 13.2 vs 8.3 months with Pembrolizumab compared with Brentuximab vedotin; about 4.9 months longer for half the group.
- A median is a midpoint: half the people did better than this and half did worse, so it is not a prediction for any one person.
- Put another way, the treated group had about 35 percent lower chance of the event at any given time (hazard ratio 0.65, likely range 0.48 to 0.88).
- This is a surrogate endpoint: it measures the cancer being controlled or absent on scans and tests, which often, but not always, translates into living longer.
- These results apply to the people the trial enrolled: Relapsed/refractory classical Hodgkin lymphoma: pembrolizumab vs brentuximab vedotin. People in a different situation may not see the same effect.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
304 participants enrolled.
Progression-free survival (median)primary
HR 0.65 (0.48–0.88) · p = 0.0027
Pembrolizumab
13.2 mo
Brentuximab vedotin
8.3 mo
| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Progression-free survival (median)primary | Pembrolizumab | 151 | 13.2 months | 0.65 (0.48–0.88) | 0.0027 | link |
| Brentuximab vedotin | 153 | 8.3 months |